NeuroXT has received FDA 510(k) clearance for NEXT-Cue, software that combines brain MRI, demographic data and cognitive test scores to help clinicians assess whether a patient with mild cognitive impairment is likely to progress to Alzheimer's dementia within five years. The output is positioned as supplementary information rather than a diagnosis, and the company has not published accuracy figures, cohort sizes or validation sites. For longevity practice, the value lies in narrowing the prognostic window during which cognitive decline remains partially modifiable.
Key Points
- FDA clears MRI-plus-cognition software estimating five-year Alzheimer's progression risk
- Inputs already collected in standard dementia workups; no new hardware
- No performance data, cohort size or validation sites disclosed publicly
Longevity Analysis
Cognitive decline is the hardest trajectory to reverse once established, which places disproportionate value on knowing where a patient sits on the curve before symptoms consolidate. A prognostic read derived from imaging and cognitive testing turns an ambiguous diagnosis into a timeline, and a timeline is what converts general brain-health advice into dated, sequenced action — sleep architecture, vascular control, metabolic correction, hearing restoration, and removal of neurotoxic exposures all carry different urgency at year one versus year five. The absence of published accuracy data means the output belongs alongside clinical judgment and established biomarkers rather than ahead of them.
Original published by Longevity.Technology, by Kyle Umipig.